Details for New Drug Application (NDA): 215243
✉ Email this page to a colleague
NDA 215243 describes RAMELTEON, which is a drug marketed by Actavis Labs Fl Inc, Andas 5 Holding, Aurobindo Pharma Ltd, Dr Reddys Labs Sa, Granules, I3 Pharms, Micro Labs, Upsher Smith Labs, Xiromed, and Zydus Pharms, and is included in ten NDAs. It is available from twenty suppliers. Additional details are available on the RAMELTEON profile page.
The generic ingredient in RAMELTEON is ramelteon. There are three drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the ramelteon profile page.
The generic ingredient in RAMELTEON is ramelteon. There are three drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the ramelteon profile page.
Summary for 215243
| Tradename: | RAMELTEON |
| Applicant: | Micro Labs |
| Ingredient: | ramelteon |
| Patents: | 0 |
Pharmacology for NDA: 215243
| Mechanism of Action | Melatonin Receptor Agonists |
Suppliers and Packaging for NDA: 215243
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| RAMELTEON | ramelteon | TABLET;ORAL | 215243 | ANDA | Micro Labs Limited | 42571-375 | 42571-375-01 | 100 TABLET in 1 BOTTLE (42571-375-01) |
| RAMELTEON | ramelteon | TABLET;ORAL | 215243 | ANDA | Micro Labs Limited | 42571-375 | 42571-375-05 | 500 TABLET in 1 BOTTLE (42571-375-05) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 8MG | ||||
| Approval Date: | Feb 9, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
